title: Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model.
abstract: Oral candidiasis is often accompanied by severe inflammation, resulting in a decline in the quality of life of immunosuppressed individuals and elderly people. To develop a new oral therapeutic option for candidiasis, a nonpathogenic commensal oral probiotic microorganism, Streptococcus salivarius K12, was evaluated for its ability to modulate Candida albicans growth in vitro, and its therapeutic activity in an experimental oral candidiasis model was tested. In vitro inhibition of mycelial growth of C. albicans was determined by plate assay and fluorescence microscopy. Addition of S. salivarius K12 to modified RPMI 1640 culture medium inhibited the adherence of C. albicans to the plastic petri dish in a dose-dependent manner. Preculture of S. salivarius K12 potentiated its inhibitory activity for adherence of C. albicans. Interestingly, S. salivarius K12 was not directly fungicidal but appeared to inhibit Candida adhesion to the substratum by preferentially binding to hyphae rather than yeast. To determine the potentially anti-infective attributes of S. salivarius K12 in oral candidiasis, the probiotic was administered to mice with orally induced candidiasis. Oral treatment with S. salivarius K12 significantly protected the mice from severe candidiasis. These findings suggest that S. salivarius K12 may inhibit the process of invasion of C. albicans into mucous surfaces or its adhesion to denture acrylic resins by mechanisms not associated with the antimicrobial activity of the bacteriocin. S. salivarius K12 may be useful as a probiotic as a protective tool for oral care, especially with regard to candidiasis.
authors.affiliation: Teikyo University Institute of Medical Mycology, Tokyo, Japan. sai31912@main.teikyo-u.ac.jp
authors.forename: Sanae A
authors.initials: SA
authors.lastname: Ishijima
authors.forename: Kazumi
authors.initials: K
authors.lastname: Hayama
authors.forename: Jeremy P
authors.initials: JP
authors.lastname: Burton
authors.forename: Gregor
authors.initials: G
authors.lastname: Reid
authors.forename: Masashi
authors.initials: M
authors.lastname: Okada
authors.forename: Yuji
authors.initials: Y
authors.lastname: Matsushita
authors.forename: Shigeru
authors.initials: S
authors.lastname: Abe
mesh_terms: D000818:Animals; D001430:Bacteriocins / Q000494:pharmacology; D002176:Candida albicans / Q000187:drug effects / Q000254:growth & development* / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D002448:Cell Adhesion / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D025301:Hyphae / Q000187:drug effects / Q000254:growth & development; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests / Q000379:methods; D019936:Probiotics / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D013291:Streptococcus / Q000145:classification / Q000254:growth & development* / Q000378:metabolism; D014059:Tongue / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D001430:Bacteriocins